{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T04:37:00Z","timestamp":1724301420496},"reference-count":15,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2016,8,30]],"date-time":"2016-08-30T00:00:00Z","timestamp":1472515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Dermatology"],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Infantile hemangiomas (<jats:styled-content style=\"fixed-case\">IH<\/jats:styled-content>s) are the most common pediatric vascular tumors. They require therapy when they cause severe complications such as ulceration, amblyopia, or airway constriction. Propranolol is the only treatment that the U.S. Food and Drug Administration has approved for complicated <jats:styled-content style=\"fixed-case\">IH<\/jats:styled-content>s and has become first\u2010line therapy for <jats:styled-content style=\"fixed-case\">IH<\/jats:styled-content>s that need to be treated. Older therapies such as systemic corticosteroids and surgery are now rarely used. Propranolol can have potentially serious adverse side effects, including bradycardia, hypotension, and hypoglycemia. There is sparse literature on the use of propranolol for <jats:styled-content style=\"fixed-case\">IH<\/jats:styled-content>s in patients with preexisting hypoglycemic conditions. We report three cases of infants with preexisting hypoglycemic conditions requiring diazoxide whose complicated hemangiomas were successfully and safely treated with oral propranolol.<\/jats:p>","DOI":"10.1111\/pde.12975","type":"journal-article","created":{"date-parts":[[2016,8,30]],"date-time":"2016-08-30T10:08:06Z","timestamp":1472551686000},"source":"Crossref","is-referenced-by-count":8,"title":["Use of Propranolol for Treating Hemangiomas in Infants with Previously Diagnosed Hypoglycemic Conditions"],"prefix":"10.1111","volume":"33","author":[{"given":"Ting\u2010Lin B.","family":"Yang","sequence":"first","affiliation":[{"name":"Division of Pediatric Dermatology Children's Hospital of Philadelphia Philadelphia PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"McMahon","sequence":"additional","affiliation":[{"name":"Division of Pediatric Dermatology Children's Hospital of Philadelphia Philadelphia PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diva D.","family":"De L\u00e9on","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes Children's Hospital of Philadelphia Philadelphia PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Treat","sequence":"additional","affiliation":[{"name":"Division of Pediatric Dermatology Children's Hospital of Philadelphia Philadelphia PA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,8,30]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2012-1691"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/0009922814535660"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.12089"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2009.01081.x"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.06.048"},{"key":"e_1_2_4_7_1","first-page":"308","article-title":"Propranolol induced hypoglycemia","volume":"12","author":"Horev A","year":"2015","journal-title":"Pediatr Endocrinol Rev"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.158"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(81)80984-5"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(66)90423-5"},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/1687-9856-2013-3"},{"key":"e_1_2_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2005.10.002"},{"key":"e_1_2_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2015.03.057"},{"key":"e_1_2_4_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5448.2012.00884.x"},{"key":"e_1_2_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(82)90280-0"},{"key":"e_1_2_4_16_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1994.4.73"}],"container-title":["Pediatric Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpde.12975","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpde.12975","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pde.12975","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T18:21:54Z","timestamp":1695752514000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pde.12975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,30]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1111\/pde.12975"],"URL":"https:\/\/doi.org\/10.1111\/pde.12975","archive":["Portico"],"relation":{},"ISSN":["0736-8046","1525-1470"],"issn-type":[{"value":"0736-8046","type":"print"},{"value":"1525-1470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,30]]}}}